The leader in adaptive diagnostics. Our PANDAA technology ensures that PCR diagnostic integrity isn’t affected by genomic variation now, or in the future.
Aldatu has received $3M from the National Institute of Allergy and Infectious Diseases at the @NIH to create the first universal molecular diagnostic for the simultaneous detection and differentiation of all variants of #Ebolavirus and #Marburg virus. https://t.co/od5OGbF4Zi
Aldatu Biosciences Adds Another Outbreak Disease to Pandemic Preparedness Portfolio - development of a universal, pan-lineage detection of Crimean-Congo Hemorrhagic Fever Virus (CCHFV), the causative agent of Crimean Congo Hemorrhagic Fever (CCHF).
https://t.co/7RRABNkO2o
This month's Harvard Innovation Labs 10 for 10 list features innovations that help people enhance and plan their lives in a variety of ways — from improving outcomes for people who want to quit smoking to offering compassionate end-of-life planning. https://t.co/j4N25JaKye
"You might call it an insurance policy against unknowns, because you don't have to change the design of your test in the future to compensate for changes," - Iain MacLeod, Aldatu CEO.
Diagnostic Developers Pursue SARS-CoV-2 Omicron Assays for Surveillance, Potential Clinical Use. The FDA thus far has not been interested in PCR tests to identify specific SARS-CoV-2 variants, but that may be changing with the emergence of Omicron. https://t.co/PSrk7YFWxu
This #WorldAidsDay2021, as we work tirelessly to end the #COVID19 pandemic, let us not forget that there's still much to be done to end the 40-year AIDS epidemic.
Access to affordable, quality health care saves lives.
On Wednesday's #WorldAIDSDay, @UNAIDS is urging countries to invest in public health systems to end AIDS & prepare for future pandemics. https://t.co/DL7FkvWnGu
We’re seeking a highly-motivated and talented Senior Research Associate to join our Assay Development team to work on developing the first universal diagnostic for Crimean-Congo hemorrhagic fever, recognized as a significant pandemic risk https://t.co/Tpj8DPvlAv
Help Save Lives
I'm participating in ResearcHERS: Women Fighting Cancer of Eastern New England to raise money for the American Cancer Society. Could you support me by making a donation? @AmericanCancer https://t.co/ZvgaR6jJLo
Aldatu's variant testing now differentiates 8 key variants - including the new Delta variant - in under two hours. Check out the product page https://t.co/0wd0NAsOir or email [email protected]#covid#testing#change
Confirmed Detection of eight (8) more genomes B.1.617.2 and two (2) community transmission of B.1.1.7 in South Africa, By Network for Genomic Surveillance in South Africa (NGS-SA), 13 May 2021
We can not believe that many of the papers highlighted by Nature were from South Africa. We would never dream to have created a network and consortium in Africa to advance global science. We feel so honored and humbled that we could help the world to face this pandemic...
. @MassDPH@MassHHS we have the capacity to help you test 1,000 #Covid samples per day for #CovidVariants. That’s every new positive case in MA tested for variants. Every day.
Calling all COVID clinical and academic researchers: Aldatu is offering FREE rapid variant testing of your positive samples to differentiate 6 key variants. Check out https://t.co/u9XR0SXSGV or email [email protected]
.@MassDPH@CDCDirector@RWalensky one of the fastest diagnostic approaches to detect and differentiate six key COVID variants. And @AldatuBio is offering free variant testing to those doing research in MA.
For everyone surprised by the @nytimes piece predicting the US will not reach herd immunity, here's a reminder that pathologist and entrepreneur Iain MacLeod of @AldatuBio made the same call back in February (and endured a lot of pushback for it):
https://t.co/Q5Ehot4c7G
As predicted in a February @statnews opinion piece (https://t.co/Ru68KoD4my) by Aldatu’s CEO, Dr. Iain MacLeod, @nytimes reports that “Reaching ‘Herd Immunity’ Is Unlikely in the U.S.” https://t.co/T9sAeoB3N2